СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О МОДУЛЯТОРАХ ОКСАЛАТНОГО НЕФРОЛИТИАЗА. I. СТИМУЛЯТОРЫ КРИСТАЛЛИЗАЦИИ
https://doi.org/10.24884/1561-6274-2009-13-1-56-72
Аннотация
В обзоре проанализированы факторы, способствующие кристаллизации оксалата кальция в почечных канальцах, и их роль в патогенезе мочекаменной болезни. Обсуждены общие представления о взаимодействии кристаллов с клетками эпителия канальцев почек. В качестве кандидатных кристалл-связывающих молекул рассмотрены сиаловая кислота, остеопонтин, фосфатидилсерин, белок, связанный с нуклеолином, аннексин II и гиалуронан, который, по-видимому, является основным индуктором кристаллизации. Поддержано мнение, согласно которому инициирующим моментом кристаллизации является обусловленное различными причинами повреждение почечного эпителия.
Об авторах
А. Ю. Жариков
Алтайский медицинский университет, г. Барнаул
Россия
Россия
кафедра фармакологии
656038, г.Барнаул, пр.Ленина, 40
Я. Ф. Зверев
Алтайский медицинский университет, г. Барнаул
Россия
Россия
кафедра фармакологии
656038, г.Барнаул, пр.Ленина, 40, (3852) 26-08-35
В. М. Брюханов
Алтайский медицинский университет, г. Барнаул
Россия
Россия
кафедра фармакологии
656038, г.Барнаул, пр.Ленина, 40
В. В. Лампатов
Алтайский медицинский университет, г. Барнаул
Россия
Россия
кафедра фармакологии
656038, г.Барнаул, пр.Ленина, 40
Список литературы
1. Kok DJ. Crystallization and stone formation inside the nephron. Scanning Microsc 1997; 10: 471-485
2. Thamilselvan S, Hackett RL, Khan SR. Lipid peroxidation in ethylene glycol induced hyperoxaluria and calcium oxalate nephrolithiasis. J Urol 1997; 157 (3): 1059-1063
3. Thamilselvan S, Khan SR. Oxalate and calcium oxalate crystals are injurious to renal epithelial cells: results of in vivo and in vitro studies. J Nephrol 1998; 11 (1): 66-69
4. Khan SR, Thamilselvan S. Nephrolithiasis: a consequence of renal epithelial cell exposure to oxalate and calcium oxalate crystals. Mol Urol 2000; 4 (4): 305-312
5. Khan SR. Crystal-induced inflammation of the kidneys: results from human studies, animal models and tissue-culture studies. Clin Exp Nephrol 2004; 8 (2): 75-88
6. Koul H, Kennington L, Nair G et al. Oxalate-induced initiation of DNA synthesis in LLC-PK1 cells, a line of renal epithelial cells. Biochem Biophys Res Commun 1994; 205: 1632-1637
7. Scheid CR, Koul H, Hill WA et al. Oxalate ion and calcium oxalate crystal interactions with renal epithelial cells. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM, eds. Kidney Stones: Medical and Surgical Management. Lippincott-Raven Publisher, Philadelphia, 1996; 129-143
8. Knoll T, Steidler A, Trojan L et al. The influence of oxalate on renal epithelial and interstitial cells. Urol Res 2004; 32 (4): 304-309
9. Sarica K, Erbagci A, Yaci F et al. Limitation of apoptotic changes in renal tubular cell injury induced by hyperoxaluria. Urol Res 2004; 32 (4): 271-277
10. Miyazawa K, Suzuki K, Ikeda R et al. Apoptosis and its related genes in renal epithelial cells of the stone-forming rat. Urol Res 2005; 33 (1): 31-38
11. Scheid CR, Koul HK, Kennington L et al. Oxalate-induced damage to renal tubular cells. Scanning Microsc 1995; 9: 1097-1105
12. Selvan R. Calcium oxalate stone disease: role of lipid peroxidation and antioxidants. Urol Res 2002; 30 (1): 35-47
13. Thamilselvan S, Khan SR, Menon M. Oxalate and calcium oxalate mediated free radical toxicity in renal epithelial cells: effect of antioxidants. Urol Res 2003; 31 (1): 3-9
14. Rashed T, Menon M, Thamilselvan S. Molecular mechanism of oxalate-induced free radical production and glutathione redox imbalance in renal epithelial cells: effect of antioxidants. Am J Nephrol 2004; 24 (5): 557-568
15. Khan SR. Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res 2005; 33 (5): 349-357
16. Green ML, Freel RW, Hatch M. Lipid peroxidation is not the underlying cause of renal injury in hyperoxaluric rats. Kidney Int 2005; 68: 2629-2638
17. Evan AP, Bledsoe SB, Smith SB, Bushinsky DA. Calcium oxalate crystal localization and osteopontin immunostaining in genetic hypercalciuric stone-forming rats. Kidney Int 2004; 65 (1): 154-161
18. Schepers MS, van Ballegooijen ES, Bangma CH, Verkoelen CF. Crystal cause acute necrotic cell death in renal proximal tubule cells but not in collecting tubule cells. Kidney Int 2005; 68 (4): 1543-1553
19. Schepers MS, van Ballegooijen ES, Bangma CH, Verkoelen CF. Oxalate is toxic to renal tubular cells only at supraphysiologic concentrations. Kidney Int 2005; 68 (4): 1660-1669
20. Verkoelen CF, Schepers MS, van Ballegooijen ES, Bangma CH. Effects of luminal oxalate or calcium oxalate on renal tubular cells in culture. Urol Res 2005; 33 (5): 321-328
21. Verkoelen CF, van der Boom BG, Houtsmuller AB et al. Increased calcium oxalate monohydrate crystal binding to injured renal tubular epithelial cells in culture. Am J Physiol Renal Physiol 1998; 274: F958-F965
22. Verkoelen CF, Van Der Boom BG, Kok DJ et al. Attachment sites for particles in the urinary tract. J Am Soc Nephrol 1999; 10 (14): S430-S435
23. Asselman M, Verkoelen CF. Crystal-cell interaction in the pathogenesis of kidney stone disease. Curr Opin Urol 2002; 12: 271-276
24. Verkoelen CF. Crystal retention in renal stone disease: A crucial role for the glycosaminoglycan hyaluronan? J Am Soc Nephrol 2006; 17: 1673-1687
25. Finlayson B, Reid F. The expectation of free and fixed particles in urinary stone disease. Invest Urol 1978; 15: 442–448
26. Vermeulen CW, Lyon ES. Mechanisms of genesis and growth of calculi. Am J Med 1968; 45: 684-692
27. Land TA, De Yoreo JJ. In situ AFM investigation of growth source activity on single crystals of canavalin. J Cryst Growth 1999; 208: 623-637
28. De Yoreo JJ, Orme CA, Land TA. Using atomic force microscopy to investigate solution crystal growth. In: Sato K, Nakajima K, Furukawa Y, eds. Advances in Crystal Growth Research. Elsevier, Amsterdam, 2000; 361-380
29. Lieske JC, Toback GF, Deganello S. Sialic acid-containing glycoproteins on renal cells determine nucleation of calcium oxalate dihydrate crystals. Kidney International 2001; 60: 1784–1791
30. De Yoreo JJ, Velikov P. Principles of crystal nucleation and growth. Rev Minerol Geochem 2003; 54: 57-93
31. De Yoreo JJ, Qin SR, Hoyer JR. Molecular modulation of calcium oxalate crystallization. Am J Physiol Renal Physiol 2006; 291 (6): F1123-F1132
32. Rabinovich YI, Esayanur M, Daosukho S et al. Adhesion force between calcium oxalate monohydrate crystal and kidney epithelial cells and possible relevance for kidney stone formation. J Colloid Interface Sci 2006; 300 (1): 131-140
33. Rabinovich YI, Daosukho S, Byer KJ et al. Direct AFM measurements of adhesion forces between calcium oxalate monohydrate and kidney epithelial cells in the presence of Ca2+ and Mg2+ ions. J Colloid Interface Sci 2008; 325 (2): 594-601
34. Тиктинский ОЛ, Александров ВП. Мочекаменная болезнь. Питер, СПб., 2000; 3-12
35. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992; 327: 1141–1152
36. Lieske JC, Leonard R, Swift H, Toback FG. Adhesion of calcium oxalate monohydrate crystals to anionic sites on the surface of renal epithelial cells. Am J Physiol Renal Physiol 1996; 270: F192-F199
37. Melick RA, Quelch KJ, Rhodes M The demonstration of sialic acid in kidney stone matrix. Clin Sci (Lond) 1980; 59 (5): 401-404
38. Hofbauer J, Fang-Kircher S, Steiner G et al. N-acetylneuraminic acids (nana): A potential key in renal calculogenesis. Urol Res 1998; 26 (1): 49–56
39. Yoshimura K, Yoshioka T, Miyake O et al. Investigation of the possible role of sialic acid in calcium oxalate urolithiasis. Eur Urol 1998; 33 (1): 111-115
40. Verkoelen CF, Van Der Boom GB, Kok DJ, Romijn JC. Sialic acid and crystal binding. Kidney Int 2000; 57: 1072–1082
41. Lieske JC, Leonard R, Toback FG. Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibited by specific anions. Am J Physiol 1995; 268: F604-F612
42. Mann PL. Membrane oligosaccharides: Structure and function during differentiation. Int Rev Cytol 1988; 12: 67–96
43. Newman RA, Delia D: Analysis of the bonding of peanut agglutinin (PNA) to leukaemic cells and its relationship to T-cell differentiation. Immunology 1983; 49: 147–153
44. Laitinen L, Lehtonen E, Virtanen I. Differential expression of galactose and N-acetylgalactosamine residues during fetal develop associment and postnatal maturation of rat glomeruli as revealed with lectin conjugates. Anat Rec 1989; 223: 311–321
45. Mandel N. Crystal–membrane interaction in kidney stone disease. J Am Soc Nephrol 1998; 5: S37–S45
46. Franzen A, Heinegеrd D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 1985; 232 (3): 715-724
47. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000; 11 (3): 279-303
48. Denhardt DT, Noda M, O’Regan AW et al. Osteopontin as a means to cope with environmental insults: regulation of inflammations KL, tissue remodeling, and cell survival. J Clin Invest 2001; 107 (9): 1055-1061
49. Mazzali M, Kipari T, Ophascharoensuk V et al. Osteopontin – A molecule for all seasons. QJM 2002; 95 (1): 3-13
50. Hudkins KL, Giachelli CM, Cui Y et al. Osteopontin expression in fetal and mature human kidney. J Am Soc Nephrol 1999; 10: 444-457
51. Xie Y, Sakatsume M, Nishi S et al. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 2001; 60: 1645-1657
52. Shiraga H, Min W, VanDusen WJ et al. Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 1992; 89: 426-430
53. Worcester EM, Beshensky AM. Osteopontin inhibits nucleation of calcium oxalate crystals. Ann N Y Acad Sci 1995; 760: 375-377
54. Hoyer JR, Asplin JR, Otvos L. Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Intern 2001; 60: 77-82
55. Gokhale JA, Glenton PA, Khan SR. Localization of Tamm-Horsfall protein and osteopontin in a rat nephrolithiasis model. Nephron 1996; 73: 456-461
56. Jiang XJ, Feng T, Chang LS et al. Expression of osteopontin mRNA in normal and stone-forming rat kidney. Urol Res 1998; 26: 389-394
57. Khan SR, Johnson JM, Peck AB et al. Expression of osteopontin in rat kidneys: induction during ethylene glycol induced calcium oxalate nephrolithiasis. J Urol 2002; 168 (3): 1173-1181
58. Wesson JA, Johnson RJ, Mazzali M et al. Osteopontin Is a Critical Inhibitor of Calcium Oxalate Crystal Formation and Retention in Renal Tubules. J Am Soc Nephrol 2003; 14: 139–147
59. Yamate T, Kohri K, Umekawa T et. al. The effect of osteopontin on the adhesion of calcium oxalate crystals to Madin-Darby canine kidney cells. Eur Urol 1996; 30 (3): 388-393
60. Yamate T, Kohri K, Umekawa T et al. Osteopontin antisense oligonucleotide inhibits adhesion of calcium oxalate crystals in Madin-Darby canine kidney cell. J Urol 1998; 160 (4): 1506-1512
61. Yamate T, Kohri K, Umekawa T et al. Interaction between osteopontin on madin darby canine kidney cell membrane and calcium oxalate crystal. Urol Int 1999; 62 (2): 81-86
62. Yasui T, Fujita K, Asai K, Kohri K. Osteopontin regulates adhesion of calcium oxalate crystals to renal epithelial cells. Int J Urol 2002; 9 (2): 100-108
63. Konya E, Umekawa T, Iguchi M, Kurita T. The role of osteopontin on calcium oxalate crystal formation. Eur Urol 2003; 43 (5): 564-571
64. Fisher LW, Hawkins GR, Tuross N, Termine JD. Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II and osteonectin from the mineral compartment of developing human bone. J Biol Chem 1987; 262: 9702-9708
65. Prince CW, Oosawa T, Bulter WT et al. Isolation, characterization, and biosynthesis of phosphorylated glycoprotein from rat bone. J Biol Chem 1987; 262: 2900-2907
66. Singh K, DeVouge MW, Mukherjee BB. Physiological properties and differential glycosylation of phosphorylated and nonphosphorylated forms of osteopontin secreted by normal rat kidney cells. J Biol Chem 1990; 265: 18696-18701
67. Kasugai S, Todescan R, Nagata T et al. Expression of bone matrix proteins associated with mineralized tissue formation by adult rat bone marrow cells in vitro: inductive effects of dexamethasone on the osteoblastic phenotype. J Cell Physiol 1991; 147: 111-120
68. Hunter GK, Kyle CL, Goldberg HA. Modulation of crystal formation by bone phosphoproteins; structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J 1994; 300: 723-728
69. Ek-Rylander B, Flores M, Wendel M et al. Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistent acid phosphatase. Modulation of osteoclast adhesion in vitro. J Biol Chem 1994; 269 (21): 14853-14856
70. Katayama Y, House CM, Udagawa N et al. Casein kinase 2 phosphorylation of recombinant rat osteopontin enhances adhesion of osteoclasts but not osteoblasts. J Cell Physiol 1998; 176 (1): 179-187
71. Razzouk S, Brunn JC, Qin C et al. Osteopontin posttranslational modifications, possibly phosphorylation, are required for in vitro bone resorption but not osteoclast adhesion. Bone 2002; 30 (1): 40-47
72. Gericke A, Qin C, Spevak L et al. Importance of phosphorylation for osteopontin regulation of biomineralization. Calcif Tissue Int 2005; 77 (1): 45-54
73. Christensen B, Kazanecki CC, Petersen TE et al. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem 2007; 282 (27): 19463-19472
74. Asselman M, Verhulst A, De Broe ME, Verkoelen CF: Calcium oxalate crystal adherence to hyaluronan-, osteopontin, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J Am Soc Nephrol 14 : 3155–3166, 2003
75. Pure E, Cuff CA. A crucial role for CD44 in inflammation. Trends Mol Med 2001; 7: 213-221
76. Verhulst A, Asselman M, Persy VP et al. Crystal retention capacity of cells in the human nephron: Involvement of CD44 and its ligands hyaluronic acid and osteopontin in the transition of a crystal binding into a nonadherent epithelium.J Am Soc Nephrol 2003; 14: 107-115
77. Aruffo A, Stamenkovic I, Melnick M et al. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61: 1303-1313
78. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996; 271: 509-512
79. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem 2002; 277 (7): 4589-4592
80. Khan SR, Shevock PN, Hackett RL. Presence of lipids in urinary stones: Results of preliminary studies. Calcif Tissue Int 1988; 42: 91-96
81. Khan SR, Shevock P, Hackett RL. In vitro precipitation of calcium oxalate in the presence of whole matrix or lipid components of the urinary stones. J Urol 1988; 139: 418-422
82. Khan SR, Maslamani SA, Atmani F et al. Membranes and their constituents as promoters of calcium oxalate crystal formation in human urine. Calcif Tissue Int 2000; 66 (2): 90-96
83. Khan SR, Glenton PA, Backov R, Talham DR. Presence of lipids in urine, crystals and stones: implications for the formation of kidney stones. Kidney Int 2002; 62:2062-2072
84. Khan SR, Kok DJ. Modulators of urinary stone formation. Front Biosci 2004; 9: 1450-1482
85. Bigelow MW, Wiessner JH, Kleinman JG, Mandel NS. Calcium oxalate-crystal membrane interactions: Dependence on membrane lipid composition. J Urol 1996; 155: 1094–1098
86. Bigelow MW, Wiessner JH, Kleinman JG, Mandel NS. Surface exposure of phosphatidylserine increases calcium oxalate crystal attachment to IMCD cells. Am J Physiol 1997; 272 (1 Pt 2): F55-62
87. Cao LC, Jonassen J, Honeyman TW, Scheid C. Oxalate-induced redistribution of phosphatidylserine in renal epithelial cells: implications for kidney stone disease. Am J Nephrol 2001; 21: 69-77
88. Wiessner JH, Hasegawa AT, Hung LY, Mandel NS. Oxalate-induced exposure of phosphatidylserine on the surface of renal epithelial cells in culture. J Am Soc Nephrol 1999; 10 (14): S441-445
89. Thiagarajan P, Tait JF. Collagen-induced exposure of anionic phospholipids in platelets and platelet-derived microparticles. J Biol Chem 1991; 266: 24302–24307
90. Князькин ИВ, Цыган ВН. Апоптоз в онкоурологии. Наука, СПб., 2007; 54-55
91. Savil J. Apoptosis and the kidney. J Am Soc Nephrol 1994; 5: 12-21
92. Wiessner JH, Hasegawa AT, Hung LY et al. Mechanisms of calcium oxalate crystal attachment to injured renal collecting duct cells. Kidney Int 2001; 59: 637–644
93. Leiser J, Molitoris BA. Disease processes in epithelia: The role of the actin cytoskeleton and altered surface membrane polarity. Biochim Biophys Acta 1993; 1225: 1-13
94. Fish EM, Molitoris BA. Alterations in epithelial polarity and the pathogenesis of disease states. N Engl J Med 1994; 330: 1580–1588
95. Riese RJ, Mandel NS, Wiessner JW et al. Cell polarity and calcium oxalate crystal adherence to cultured collecting duct cells. Am J Physiol 1992; 262: F177–F184
96. Sorokina EA, Kleinman JG. Cloning and preliminary characterization of a calcium-binding protein closely related to nucleolin on the apical surface of inner medullary collecting duct cells. J Biol Chem 1999; 274 (39): 27491–27496
97. Semenkovich CF, Ostlund RE Jr, Olson MO, Yang JW. A protein partially expressed on the surface of HepG2 cells that binds lipoproteins specifically is nucleolin. Biochemistry 1990; 29 (41): 9708-9713
98. Jordan P, Heid H, Kinzel V, Kubler D. Major cell surface-located protein substrates of an ecto-protein kinase are homologs of known nuclear proteins. Biochemistry 1994; 33 (49): 14696-14706
99. Krantz S, Salazar R, Brandt R et al. Purification and partial amino acid sequencing of a fructosyllysine-specific binding protein from cell membranes of the monocyte-like cell line U937. Biochim Biophys Acta 1995; 1266 (1): 109-112
100. de Verdugo UR, Selinka HC, Huber M et. al. Characterization of a 100-kilodalton binding protein for the six serotypes of coxsackie B viruses. J Virol 1995; 69 (11): 6751-6757
101. Xie J, Briggs JA, Olson MO et al. Human myeloid cell nuclear differentiation antigen binds specifically to nucleolin. J Cell Biochem 1995; 59 (4): 529-536
102. Take M, Tsutsui J, Obama H et al. Identification of nucleolin as a binding protein for midkine (MK) and heparin-binding growth associated molecule (HB-GAM). J Biochem 1994; 116 (5): 1063-1068
103. Hovanessian AG, Puvion-Dutilleul F, Nisole S et al. The cell-surface-expressed nucleolin is associated with the actin cytoskeleton. Exp Cell Res 2000; 261: 312–328
104. Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989; 56 (3): 379-390
105. Schmidt-Zachmann MS, Dargemont C, Kьhn LC, Nigg EA. Nuclear export of proteins: the role of nuclear retention. Cell 1993; 74 (3): 493-504
106. Nigg EA. Nucleocytoplasmic transport: Signals, mechanisms and regulation. Nature 1997; 386: 779-787
107. Kleinman HK, Weeks BS, Cannon FB et al. Identification of a 110-kDa nonintegrin cell surface lamininbinding protein which recognizes an A chain neurite-promoting peptide. Arch Biochem Biophys 1991; 290: 320–325
108. Kibbey MC, Johnson B, Petryshyn R et al. A 110-kD nuclear shuttling protein, nucleolin, binds to the neurite-promoting IKVAV site of laminin-1. J Neurosci Res 1995; 42: 314–322
109. Sorokina EA, Wesson JA, Kleinman JG. An acidic peptide sequence of nucleolin-related protein can mediate the attachment of calcium oxalate to renal tubule cells. J Am Soc Nephrol 2004; 15: 2057–2065
110. Kumar V, Farell G, Deganello S, Lieske JC. Annexin II is present on renal epithelial cells and binds calcium oxalate monohydrate crystals. Am Soc Nephrol 2003; 14: 289-297
111. Gerke V, Moss SE. Annexins: From structure to function. Physiol Rev 2002; 82: 331–371
112. Siever DA, Erickson HP. Extracellular annexin II. Int J Biochem Cell Biol 1997; 29: 1219–1223
113. Ma AS, Ozers LJ. Annexins I and II show differences in subcellular localization and differentiation-related changes in human epidermal keratinocytes. Arch Dermatol Res 1996; 288: 596–603
114. Hajjar KA, Guevara CA, Lev E et al. Interaction of the fibrinolytic receptor, annexin II, with the endothelial cell surface. Essential role of endonexin repeat 2. J Biol Chem 1996; 271: 21652–21659
115. Raynor CM, Wright JF, Waisman DM, Pryzdial EL. Annexin II enhances cytomegalovirus binding and fusion to phospholipid membranes. Biochemistry1999; 38: 5089–5095
116. Baran DT, Quail JM, Ray R et al. Annexin II is the membrane receptor that mediates the rapid actions of 1a,25-dihydroxyvitamin D 3. J Cell Biochem 2000; 78: 34–46
117. Carr G, Simmons NL, Sayer JA. Disruption of clc-5 leads to a redistribution of annexin A2 and promotes calcium crystal agglomeration in collecting duct epithelial cells. Cell Mol Life Sci 2006; 63: 367–377
118. Chiang Y, Schneiderman MH, Vishwanatha JK. Annexin II expression is regulated during mammalian cell cycle. Cancer Res 1993; 53: 6017–6021
119. Lieske JC, Spargo BH, Toback FG. Endocytosis of calcium oxalate crystals and proliferation of renal tubular epithelial cells in a patient with type 1 primary hyperoxaluria. J Urol 1992; 148: 1517–1519
120. Lieske JC, Swift H, Martin T et al. Renal epithelial cells rapidly bind and internalize calcium oxalate monohydrate crystals. Proc Natl Acad Sci USA 1994; 91: 6987–6991
121. Lieske JC, Toback FG. Regulation of renal epithelial cell endocytosis of calcium oxalate monohydrate crystals. Am J Physiol 1993; 264: F800–F807
122. Lieske JC, Walsh-Reitz MM, Toback FG. Calcium oxalate monohydrate crystals are endocytosed by renal epithelial cells and induce proliferation. Am J Physiol 1992; 262: F622–F630
123. Hammes MS, Lieske JC, Pawar S et al. Calcium oxalate monohydrate crystals stimulate gene expression in renal epithelial cells. Kidney Int 1995; 48: 501–509
124. Lieske JC, Hammes MS, Hoyer JR, Toback FG. Renal cell osteopontin production is stimulated by calcium oxalate monohydrate crystals. Kidney Int 1997; 51: 679–686
125. Scheiffele P, Verkade P, Fra AM et al. Caveolin-1 and -2 in the exocytic pathway of MDCK cells. J Cell Biol 1998; 140: 795–806
126. Carozzi AJ, Ikonen E, Lindsay MR, Parton RG. Role of cholesterol in developing T-tubules: analogous mechanisms for T-tubule and caveolae biogenesis. Traffic 2000; 1: 326–341
127. Verkoelen CF, van der Boom BG, Romijn JC. Identification of hyaluronan as a crystal-binding molecule at the surface of migrating and proliferating MDCK cells. Kidney Int 2000; 58: 1045–1054
128. Toole BP. Hyaluronan in morphogenesis. J Intern Med 1997; 242: 35-40
129. Lee JY, Spicer AP. Hyaluronan: A multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol 2000; 12: 581–586
130. Toole BP. Hyaluronan is not just a goo! J Clin Invest 2000; 106: 335–336
131. Stern R. Hyaluronan catabolism: A new metabolic pathway. Eur J Cell Biol 2004; 83: 317–325
132. Weigel PH, Hascall VC, Tammi M. Hyaluronan synthases. J Biol Chem 1997; 272: 13997–14000
133. Laurent TC, Lilja K, Brunnberg L et al. Urinary excretion of hyaluronan in man. Scand J Clin Lab Invest 1987; 47: 793–799
134. Sun L, Feusi E, Sibalic A et al. Expression profile of hyaluronidase mRNA transcripts in the kidney and in renal cells. Kidney Blood Press 1998; 21: 413–418
135. Knudson W, Chow G, Knudson CB. CD44-mediated uptake and degradation of hyaluronan. Matrix Biol 2002; 21: 15–23
136. Camenisch TD, Spicer AP, Brehm-Gibson T et al. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J Clin Invest 2000; 106: 349–360
137. Belsky E, Toole BP. Hyaluronate and hyaluronidase in the developing chick embryo kidney. Cell Differ 1983; 12: 61–66
138. Asselman M, Verhulst A, Van Ballegooijen ES, Bangma CH et al. Hyaluronan is apically secreted and expressed by proliferating or regenerating renal tubular cells. Kidney Int 2005; 68: 71–83
139. Кабилова НО. Влияние вазопрессина, dDAVP и AVP-A на экспрессию генов гиалуронан-синтазы 2 и гиалуронидазы 1 и 2 в почке крыс Вистар и Браттлборо с наследственным дефектом синтеза вазопрессина. В: Тез докл YI Сибирск физиол. съезда. Принтэкспресс, Барнаул, 2008; 2: 130
140. Ginetzinsky AG. Role of hyaluronidase in the re-absorption of water in renal tubules: The mechanism of action of the antidiuretic hormone. Nature 1958; 182: 1218-1219
141. Ginetzinsky AG. Relationship between urinary hyaluronidase and diuresis. Nature 1961; 189: 235-237
142. Иванова ЛН, Кабилова НО, Бондарь АА. Влияние dDAVP, агониста V 2 рецепторов вазопрессина, на экспрессию генов гиалуронидазы 1 и 2 типов в почке крыс Вистар и Браттлборо. Рос физиол журн им ИМ Сеченова 2007; 93 (5): 494-504
143. Hansell P, Goransson V, Odlind C et al. Hyaluronan content in the kidney in different states of body hydration. Kidney Int 2000; 58: 2061–2068
144. Ivanova LN, Melidi NN. Effects of vasopressin on hyaluronate hydrolase activities and water permeability in the frog urinary bladder. Pflugers Arch 2001; 443: 72–77
145. Law RO, Rowen D. The influence of hyaluronidase on urinary and renal medullary composition following antidiuretic stimulus in the rat. J Physiol 1981; 311: 341–354
146. Sibalic V, Fan X, Loffing J, Wuthrich RP. Upregulated renal tubular CD44, hyaluronan, and osteopontin in kdkd mice with interstitial nephritis. Nephrol Dial Transplant 1997; 12: 1344–1353
147. Goransson V, Johnsson C, Jacobson A et al. Renal hyaluronan accumulation and hyaluronan synthase expression after ischaemia-reperfusion injury in the rat. Nephrol Dial Transplant 2004; 19: 823–830
148. Lewington AJ, Padanilam BJ, Martin DR, Hammerman MR. Expression of CD44 in kidney after acute ischemic injury in rats. Am J Physiol Regul Integr 2000; 278: R247–R254
149. Verhulst A, Asselman M, De Naeyer S et al. Preconditioning of the distal tubular epithelium of the human kidney precedes nephrocalcinosis. Kidney Int 2005; 68: 1643-1647
150. Knudson W, Knudson CB. Assembly of a chondrocyte-like pericellular matrix on non-chondrogenic cells. Role of the cell surface hyaluronan receptors in the assembly of a pericellular matrix. J Cell Sci 1991; 99: 227-235
151. Schepers MSJ, van der Boom BG, Romijn JC et al. Urinary crystallization inhibitors do not prevent crystal binding. J Urol 2002; 167: 1844-1847
152. Evan AP, Lingeman JE, Coe FL et al. Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 2003; 111 (5): 607–616
Рецензия
Для цитирования:
Жариков А.Ю., Зверев Я.Ф., Брюханов В.М., Лампатов В.В. СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О МОДУЛЯТОРАХ ОКСАЛАТНОГО НЕФРОЛИТИАЗА. I. СТИМУЛЯТОРЫ КРИСТАЛЛИЗАЦИИ. Нефрология. 2009;13(1):56-72. https://doi.org/10.24884/1561-6274-2009-13-1-56-72
For citation:
Jaricov A.Yu., Zverev Ya.F., Brukhanov V.M., Lampatov V.V. THE CURRENT CONCEPTIONS ABOUT THE MODULATORS OF THE OXALATE NEPHROLYTHIASIS. I. STIMULATORS OF CRYSTALLIZATION. Nephrology (Saint-Petersburg). 2009;13(1):56-72. (In Russ.) https://doi.org/10.24884/1561-6274-2009-13-1-56-72
Просмотров:
342
Послать статью по эл. почте 